Bioequivalence Study of Erythromycin Cyclic 11,12-Carbonate Powder Suspension,capsule and Tablet

YANG Guo-ping,OUYANG Dong-sheng,CHEN Ben-mei,PEI Qi,TAN Hong-yi,HUANG Zhi-jun,LIU Chang,YUAN Hong
DOI: https://doi.org/10.3969/j.issn.1007-7669.2007.04.002
2007-01-01
Abstract:AIM:To evaluate the bioequivalence of three formulations of erythromycin cyclic 11,12- carbonate,powder suspension,capsules and tablets,in human plasma.METHODS:An open randomized, three periods crossover study on 18 healthy male volunteers was carried out.The concentrations of erythromycin cyclic 11,12-carbonate in plasma were determined by HPLC-MS after a single oral dose of 750 mg erythromycin cyclic 11,12-carbonate powder suspension,capsules and tablets taking separately and individually in a crossover design.RESULTS:The pharmacokinetic parameters of reference preparation and test preparations of powder suspension and capsules were as follows:c_(max)(1375±s 261)μg.L~(-1),(1303±356)μg·L~(-1)and (1307±305)μg·L~(-1);t_(max)(2.4±0.8)h,(2.4±1.0)h and(2.9±0.9)h;AUC_(0-48)(13302±4369)μg·h·L~(-1),(13596±5519)μg·h·L~(-1)and(13564±4825)μg·h·L~(-1)respectively.The correlative bioavailabilities of the test formulation were(102±17)% and(102±15)%.CONCLUSION:Erythromycin cyclic 11,12-carbonate powder suspension and capsules are bioequivalence with the reference tablets.
What problem does this paper attempt to address?